Table 2.
Summary of findings from vaccine impact studies from early-introduction countries
| Location | Vaccine | Key Findings from Major Vaccine Impact Studies |
| The Americas | ||
| Brazil | RV1 | Vaccine effectiveness of 85% (95% CI: 54–95) against G2P[4] rotavirus gastroenteritis among children 6–11 mo of age;71 ∼22% reduction in diarrhea-associated mortality rates and ∼17% reduction in diarrhea-associated hospitalization rates among children <5 y during postvaccine years 2007–200972 |
| El Salvador | RV1 | Vaccine effectiveness of 74% against severe rotavirus gastroenteritis (Vesikari score ≥11) and 88% against very severe rotavirus gastroenteritis (Vesikari score ≥15);73 ∼69–81% decline in rotavirus hospitalizations rates and ∼35–48% decline in all-cause diarrhea events (outpatient and inpatient) among children <5 y in 2008 and 200974 |
| Mexico | RV1 | ∼35% reduction in diarrhea-related mortality rate among children <5 y in 2008; 75 ∼11–40% reduction in all-cause diarrhea hospitalizations among children <5 y in 2008 and 200976 |
| Nicaragua | RV5 | Vaccine effectiveness of 52–63% against severe rotavirus gastroenteritis (Vesikari score ≥11) and 73–86% against very severe rotavirus gastroenteritis (Vesikari score ≥15) in the first year post vaccine introduction77 |
| Panama | RV1 | ∼22–37% reduction in all-cause diarrhea hospitalizations among children <5 y in 2007 and 200878 |
| US | RV1 and RV5 | RV5 vaccine effectiveness of 83–86% against rotavirus gastroenteritis ED visits or hospitalizations over 2 rotavirus seasons, 2008–2009;79 ∼46% decline in all-cause diarrhea hospitalization rates among children <5 y in 18 states in 2008 resulting in ∼40,000 to 60,000 fewer gastroenteritis-related hospitalizations;80 delayed, shorter rotavirus seasons and a sustained reduction in the number of rotavirus antigen-positive tests through the 2009–2010 rotavirus season72 |
| Europe | ||
| Austria | RV1 and RV5 | Vaccine effectiveness of 60–97% against rotavirus hospitalization; ∼79–87% reduction in rotavirus hospitalizations among children age-eligible to receive vaccine in 2008 and 200981 |
| Belgium | RV1 and RV5 | ∼65–83% reduction in rotavirus hospitalizations during postvaccine years 2007–201082 |
| Australia | RV1 and RV5 | Vaccine effectiveness of 89–94% against rotavirus hospitalizations; ∼53–93% reduction in rotavirus hospitalizations among children ≤3 y83 |